Using a quantitative measure of diabetes risk in clinical practice to target and maximize diabetes prevention interventions

Clinical Diabetes

Volumn 31, Issue 2, 2013, Pages 82-89

  Rich, Paul A ^a   Shaefer, Charles F ^b   Parkin, Christopher G ^c   Edelman, Steven V ^d  

^a Comprehensive Physician Associates LLC ^*  (United States)

^b University Primary Care Physicians   (United States)

^c CGParkin Communications Inc   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FERRITIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 2 RECEPTOR ALPHA; METFORMIN;

ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; EATING HABIT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE AND RELATED PHENOMENA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICAL ACTIVITY; PREDX TEST; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; RISK FACTOR;

EID: 84876403305     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.31.2.82     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention: National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, Ga., U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
2. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
3. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD: Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104-1115, 2011
4. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368:1096-1105, 2006
5. Geiss LS, James C, Gregg EW, Albright A, Williamson DF, Cowie CC: Diabetes risk reduction behaviors among U.S. adults with prediabetes. Am J Prev Med 38:403-409, 2010
6. American Diabetes Association: Standards of medical care in diabetes-2012. Diabetes Care 35:S11-S63, 2012
7. Nichols GA, Hillier TA, Brown JB: Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 30:228-233, 2007
8. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156:1070-1077, 2002
9. Urdea M, Kolberg J, Wilber J, Gerwien R, Moler E, Rowe M, Jorgensen P, Hansen T, Pedersen O, Jorgensen T, Borch-Johnsen K: Validation of a multimarker model for assessing risk of type 2 diabetes from a fiveyear prospective study of 6784 Danish people (Inter99). J Diabetes Sci Technol 3:748-755, 2009
10. Kolberg JA, Jorgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, Rowe MW, Urdea MS, Xu XM, Hansen T, Pedersen O, Borch-Johnsen K: Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care 32:1207-1212, 2009
11. Lyssenko V, Jorgensen T, Gerwien RW, Hansen T, Rowe MW, McKenna MP, Kolberg J, Pedersen O, Borch-Johnsen K, Groop L: Validation of a multi-marker model for the prediction of incident type 2 diabetes mellitus: combined results of the Inter99 and Botnia studies. Diab Vasc Dis Res 9:59-67, 2012
12. Shafizadeh TB, Moler EJ, Kolberg JA, Nguyen UT, Hansen T, Jorgensen T, Pedersen O, Borch-Johnsen K: Comparison of accuracy of diabetes risk score and components of the metabolic syndrome in assessing risk of incident type 2 diabetes in Inter99 cohort. PLoS One 6:e22863, 2011
13. Geberhiwot T, Haddon A, Labib M: HbA1c predicts the likelihood of having impaired glucose tolerance in high-risk patients with normal fasting plasma glucose. Ann Clin Biochem 42:193-195, 2005
14. Selvin E, Crainiceanu CM, Brancati FL, Coresh J: Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 167:1545-1551, 2007
15. Stern MP, Fatehi P, Williams K, Haffner SM: Predicting future cardiovascular disease. Diabetes Care 25:1851-1856, 2002
16. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW: Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population. Diabetes Care 29:1263-1268, 2006
17. Fajans SS, Herman WH, Oral EA: Insufficient sensitivity of hemoglobin A1C determination in diagnosis or screening of early diabetic states. Metabolism 60:86-91, 2011
18. James C, Bullard KM, Rolka DB, Rolka DB, Geiss LS, Williams DE, Cowie CC, Albright A, Gregg EW: Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care 34:387-391, 2011
19. Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS: Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 33:2184-2189, 2010
20. Malkani S, Mordes JP: Implications of using hemoglobin A1C for diagnosing diabetes mellitus. Am J Med 124:395-401, 2011
21. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart J-C, James WPT, Loria CM, Smith SC: Harmonizing the metabolic syndrome. Circulation 120:1640-1645, 2009
22. Kolberg JA, Gerwien RW, Watkins SM, Wuestehube LJ, Urdea M: Biomarkers in type 2 diabetes: improving risk stratification with the PreDx (R) Diabetes Risk Score. Expert Rev Mol Diagn 11:775-792, 2011
23. Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X, Hu Z-X, Juan-L, Xiao J-Z, Cao H-B, Liu P-A, Jiang X-G, Jiang Y-Y, Wang J-P, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
24. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
25. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA: The quality of health care delivered to adults in the United States. N Engl J Med 348:2635-2645, 2003
26. Blendon RJ, Schoen C, DesRoches CM, Osborn R, Zapert K, Raleigh E: Confronting competing demands to improve quality: a five-country hospital survey. Health Aff (Millwood) 23:119-135, 2004
27. Yarnell K, Ostbye T, Krause K, Pollak K, Gradison M, Michener L: Family physicians as team leaders: "Time to share the care." Prev Chronic Dis 6:A59, 2009
28. DPP Research Group: The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 61:1075-1081, 2006
29. Bristol-Myers Squibb: Glucophage (metformin hydrochloride) package insert. Bristol-Myers Squibb Company, New York, 2009
30. Tuomilehto J, Lindstrom J, White M, Penn L, Walker M, Mathers JC, den Boer ATH, Blaak EE, Gerwien RW, Kolberg JA, Rowe MW: Changes in a diabetes risk score due to intensive lifestyle intervention in the European Diabetes Prevention Study (EDIPS). Diabetes 60 (Suppl. 1):A366, 2011
31. Sullivan SD, Garrison LP Jr, Rinde H, Kolberg J, Moler EJ: Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. J Med Econ 14:609-616, 2011
32. Markowitz SM, Park ER, Delahanty LM, O'Brien KE, Grant RW: Perceived impact of diabetes genetic risk testing among patients at high phenotypic risk for type 2 diabetes. Diabetes Care 34:568-573, 2011
33. Chapin RB, Williams DC, Adair RF: Diabetes control improved when inner-city patients received graphic feedback about glycosylated hemoglobin levels. J Gen Intern Med 18:120-124, 2003
34. Levetan CS, Dawn KR, Robbins DC, Ratner RE: Impact of computer-generated personalized goals on HbA(1c). Diabetes Care 25:2-8, 2002
35. Conrad SE: A comparative study of the use of the PreDx® Diabetes Risk Score (DRS) in primary care: how are medical management and patient outcomes affected? Presented at the Fourth International Congress on Prediabetes and the Metabolic Syndrome, 6-9 April 2011, Madrid, Spain
36. Rowe M, Bergman RN, Wagenknecht LE, Kolberg JA: Performance of a multimarker diabetes risk score in the Insulin Resistance Atherosclerosis Study (IRAS), a multi-ethnic US cohort. Diabetes Metab Res Rev. 28:519-526, 2012